Investigator Daniel Petrylak summarizes the key results of the phase II EV-201 trial of the antibody–drug conjugate enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer (2:42).
12-06-2019 | Urothelial cancer | Video | Article
Investigator Daniel Petrylak summarizes the key results of the phase II EV-201 trial of the antibody–drug conjugate enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer (2:42).